Literature DB >> 31132297

RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.

Tomohiro Watanabe1,2, Kosuke Minaga1, Ken Kamata1, Toshiharu Sakurai1, Yoriaki Komeda1, Tomoyuki Nagai1, Atsushi Kitani2, Masaki Tajima2, Ivan J Fuss2, Masatoshi Kudo1, Warren Strober2.   

Abstract

Previous studies have shown that inhibition of receptor-interacting serine/threonine kinase (RICK) (also known as RIP2) results in amelioration of experimental colitis. This role has largely been attributed to nucleotide-binding oligomerization domain 2 (NOD2) signaling since the latter is considered a major inducer of RICK activation. In this study, we explored the molecular mechanisms accounting for RICK-mediated inhibition of inflammatory bowel disease (IBD). In an initial series of studies focused on trinitrobenzene sulfonic acid (TNBS)-colitis and dextran sodium sulfate (DSS)-colitis we showed that down-regulation of intestinal RICK expression in NOD2-intact mice by intra-rectal administration of a plasmid expressing RICK-specific siRNA was accompanied by down-regulation of pro-inflammatory cytokine responses in the colon and protection of the mice from experimental colitis. Somewhat surprisingly, intra-rectal administration of RICK-siRNA also inhibited TNBS-colitis and DSS-colitis in NOD2-deficient and in NOD1/NOD2-double deficient mice. In complementary studies of humans with IBD we found that expression of RICK, cellular inhibitor of apoptosis protein 2 (cIAP2) and downstream signaling partners were markedly increased in inflamed tissue of IBD compared to controls without marked elevations of NOD1 or NOD2 expression. In addition, the increase in RICK expression correlated with disease activity and pro-inflammatory cytokine responses. These studies thus suggest that NOD1- or NOD2-independenent activation of RICK plays a major role in both murine experimental colitis and human IBD. © The Japanese Society for Immunology. 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  NOD2; RICK/RIP2; inflammatory bowel diseases

Mesh:

Substances:

Year:  2019        PMID: 31132297      PMCID: PMC6939834          DOI: 10.1093/intimm/dxz045

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  48 in total

Review 1.  Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases.

Authors:  Vinayak Vittal; Mikaela D Stewart; Peter S Brzovic; Rachel E Klevit
Journal:  J Biol Chem       Date:  2015-07-17       Impact factor: 5.157

2.  Functional characterization of the NF-kappaB binding site in the human NOD2 promoter.

Authors:  Chaofeng Hu; Liping Sun; Yiling Hu; Daxiang Lu; Huadong Wang; Suisheng Tang
Journal:  Cell Mol Immunol       Date:  2010-05-03       Impact factor: 11.530

3.  Stress response protein cirp links inflammation and tumorigenesis in colitis-associated cancer.

Authors:  Toshiharu Sakurai; Hiroshi Kashida; Tomohiro Watanabe; Satoru Hagiwara; Tsunekazu Mizushima; Hideki Iijima; Naoshi Nishida; Hiroaki Higashitsuji; Jun Fujita; Masatoshi Kudo
Journal:  Cancer Res       Date:  2014-09-03       Impact factor: 12.701

4.  Chronic Fibro-Inflammatory Responses in Autoimmune Pancreatitis Depend on IFN-α and IL-33 Produced by Plasmacytoid Dendritic Cells.

Authors:  Tomohiro Watanabe; Kouhei Yamashita; Yasuyuki Arai; Kosuke Minaga; Ken Kamata; Tomoyuki Nagai; Yoriaki Komeda; Mamoru Takenaka; Satoru Hagiwara; Hiroshi Ida; Toshiharu Sakurai; Naoshi Nishida; Warren Strober; Masatoshi Kudo
Journal:  J Immunol       Date:  2017-04-03       Impact factor: 5.422

5.  Secretory mediators regulate Nod2-induced tolerance in human macrophages.

Authors:  Matija Hedl; Clara Abraham
Journal:  Gastroenterology       Date:  2010-09-18       Impact factor: 22.682

6.  RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems.

Authors:  Koichi Kobayashi; Naohiro Inohara; Lorraine D Hernandez; Jorge E Galán; Gabriel Núñez; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Nature       Date:  2002-03-14       Impact factor: 49.962

7.  Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease.

Authors:  Eike Hollenbach; Michael Vieth; Albert Roessner; Manfred Neumann; Peter Malfertheiner; Michael Naumann
Journal:  J Biol Chem       Date:  2005-02-03       Impact factor: 5.157

8.  Chronic stimulation of Nod2 mediates tolerance to bacterial products.

Authors:  Matija Hedl; Jing Li; Judy H Cho; Clara Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-21       Impact factor: 11.205

9.  NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2.

Authors:  Yibin Yang; Catherine Yin; Amit Pandey; Derek Abbott; Christopher Sassetti; Michelle A Kelliher
Journal:  J Biol Chem       Date:  2007-10-18       Impact factor: 5.157

Review 10.  Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.

Authors:  Warren Strober; Naoki Asano; Ivan Fuss; Atsushi Kitani; Tomohiro Watanabe
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

View more
  7 in total

1.  Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2.

Authors:  Madelyn H Miller; Michael G Shehat; Justine T Tigno-Aranjuez
Journal:  Immunohorizons       Date:  2020-12-18

2.  Gut microbiome alterations in type 1 autoimmune pancreatitis after induction of remission by prednisolone.

Authors:  K Kamata; T Watanabe; K Minaga; A Hara; I Sekai; Y Otsuka; T Yoshikawa; A-M Park; M Kudo
Journal:  Clin Exp Immunol       Date:  2020-09-21       Impact factor: 4.330

3.  Expression levels of cellular inhibitor of apoptosis proteins and colitogenic cytokines are inversely correlated with the activation of interferon regulatory factor 4.

Authors:  Sho Masaki; Tomohiro Watanabe; Yasuyuki Arai; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Yasuo Otsuka; Yasuhiro Masuta; Tomoe Yoshikawa; Ryutaro Takada; Ken Kamata; Kosuke Minaga; Kouhei Yamashita; Masatoshi Kudo
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 5.732

4.  Case Report: A Case of Intestinal Behçet's Disease Exhibiting Enhanced Expression of IL-6 and Forkhead Box P3 mRNA After Treatment With Infliximab.

Authors:  Keisuke Yoshikawa; Tomohiro Watanabe; Ikue Sekai; Ryutaro Takada; Akane Hara; Masayuki Kurimoto; Yasuhiro Masuta; Yasuo Otsuka; Tomoe Yoshikawa; Sho Masaki; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Takaaki Chikugo; Masatoshi Kudo
Journal:  Front Med (Lausanne)       Date:  2021-05-14

Review 5.  RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.

Authors:  Hajime Honjo; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

Review 6.  Alterations of autophagic and innate immune responses by the Crohn's disease-associated ATG16L1 mutation.

Authors:  Natsuki Okai; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Hajime Honjo; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

7.  Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease.

Authors:  Kosuke Minaga; Tomohiro Watanabe; Akane Hara; Ken Kamata; Shunsuke Omoto; Atsushi Nakai; Yasuo Otsuka; Ikue Sekai; Tomoe Yoshikawa; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Masatoshi Kudo
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.